| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526734 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2033
(8 years from now) | |
| US9808468 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2035
(10 years from now) | |
| US9649318 | ICEUTICA OPERATIONS | Formulation of meloxicam |
Mar, 2035
(10 years from now) | |
Vivlodex is owned by Iceutica Operations.
Vivlodex contains Meloxicam.
Vivlodex has a total of 3 drug patents out of which 0 drug patents have expired.
Vivlodex was authorised for market use on 22 October, 2015.
Vivlodex is available in capsule;oral dosage forms.
Vivlodex can be used as management of osteoarthritis pain by administering 10 mg of meloxicam.
The generics of Vivlodex are possible to be released after 31 March, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Management of osteoarthritis pain by administering 10 mg of meloxicam
Dosage: CAPSULE;ORAL
How can I launch a generic of VIVLODEX before it's drug patent expiration?
More Information on Dosage
VIVLODEX family patents
